Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 5;73(7):e1772-e1774.
doi: 10.1093/cid/ciaa1809.

Reply to Neves

Melanie R Nicol  1 , David R Boulware  1 , Radha Rajasingham  1
Affiliations
Comment

Reply to Neves

Melanie R Nicol et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A, Risk of COVID-19–compatible illness by days from highest risk exposure to study enrollment. Day 1 = same day enrollment as exposure with study medicines shipped overnight (Monday–Saturday in the United States, Monday–Sunday in Canada). Analysis is by intent-to-treat, as specified in the original protocol, including all who were randomized. This includes those who were randomized but never started hydroxychloroquine and who had a 3.1% (2/65) incidence of illness. B, Risk of COVID-19–compatible illness from the time of last exposure to severe acute respiratory syndrome coronavirus 2 polymerase chain reaction–positive contact to the time of starting the study drug. Analysis is by modified intent-to-treat analysis, excluding those who never started the study medicine or withdrew from the trial. Abbreviation: COVID-19, coronavirus disease 2019.
See this image and copyright information in PMC

Comment on

References

    1. Neves FS. Dose-response effects of hydroxychloroquine on prophylaxis against SARS-CoV-2/COVID-19 infection. Clin Infect Dis 2020; In press. - PMC - PubMed
    1. Rajasingham R, Bangdiwala AS, Nicol MR, et al. . Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa1571. - DOI - PMC - PubMed
    1. Abella BS, Jolkovsky EL, Biney BT, et al. . Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med 2020; doi: 10.1001/jamainternmed.2020.6319. - DOI - PMC - PubMed
    1. Boulware DR, Pullen MF, Bangdiwala AS, et al. . A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020; 383:517–25. - PMC - PubMed
    1. Maisonnasse P, Guedj J, Contreras V, et al. . Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 2020; 585:584–7. - PubMed